Cita APA

Babiker, H. M., Byron, S. A., Hendricks, W. P. D., Elmquist, W. F., Gampa, G., Vondrak, J., . . . Gordon, M. S. (2018). E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs.

Chicago Style Citation

Babiker, Hani M., et al. "E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-mutated Metastatic Malignant Melanoma With Brain Metastases." Invest New Drugs 2018.

Cita MLA

Babiker, Hani M., et al. "E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-mutated Metastatic Malignant Melanoma With Brain Metastases." Invest New Drugs 2018.